Navigation Links
FDA Puts Partial Hold on Avandia Safety Study
Date:7/21/2010

WEDNESDAY, July 21 (HealthDay News) -- No new patients will be permitted to enroll in a safety study of the controversial diabetes drug Avandia until further notice, the U.S. Food and Drug Administration announced Wednesday.

But under the partial clinical trial hold, those patients already enrolled in the TIDE (Thiazolidinedione Intervention With Vitamin D Evaluation) trial will be allowed to continue to participate, the agency said in a news release.

An FDA advisory panel last week ruled that Avandia (rosiglitazone) does boost users' heart risks, but it also decided that the drug should stay on the market because there's no definitive evidence of an increased risk.

The FDA said Wednesday that it is evaluating available data on Avandia's safety and the discussions from last week's advisory panel meeting. When the review is complete, the agency will inform the public about the findings and what they mean for the drug's status and the TIDE trial.

GlaxoSmithKline, which makes Avandia, was told by the FDA to update researchers, institutional review boards and ethics committees involved in the TIDE trial about new safety information presented at the FDA advisory panel meeting. That information can be used to update informed consent information for people already enrolled in the TIDE trial, the FDA said.

GSK agreed to conduct the TIDE trial in 2007 after concerns about the safety of Avandia first became public. The goal of the trial is to determine whether Avandia poses greater heart risks than a competing drug called Actos.

In a news release, the drug company confirmed that it will suspend enrollment of new patients in the TIDE trial and send a summary of recent safety data and a summary of the FDA advisory panel meeting to all TIDE researchers and institutional review boards.

"This pause in enrollment will give clinical trial investigators and patients time to learn about the data presented to the FD
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Lacosamide validated as promising therapy for uncontrolled partial-onset seizures
2. Deep brain stimulation reduces epileptic seizures in patients with refractory partial and secondarily generalized seizures
3. Study shows partial lung removal favorable over full removal as treatment for lung cancer
4. Hip surgery success partially predicted by number of other existing conditions
5. Diabetes Drugs Avandia, Actos Tied to Fractures in Women
6. Remove Diabetes Drug Avandia From Market: FDA Reports
7. Remove Diabetes Drug Avandia From Market: FDA Documents
8. FDA Says It Hasnt Decided Whether to Pull Diabetes Drug Avandia Off the Market
9. FDA: No Decision on Whether to Pull Diabetes Drug Avandia Off the Market
10. Maher Law Firm Warns Avandia Users - NY Times Reports - FDA Recommends Recall of Avandia
11. Diabetes Drug Avandia Ups Heart Risk, Reviews Conclude
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Puts Partial Hold on Avandia Safety Study
(Date:8/29/2014)... of clinical trials based on administering antidepressants for ... that more trials are needed to determine whether ... on a regular basis., Dr. Ian Gilron, a ... the Department of Anesthesiology, and his team of ... the use of antidepressants for pain relief post-surgery ...
(Date:8/29/2014)... 2, 2014) A team of scientists from the ... breakthrough discovery of a process to expand production of ... could have implications that extend beyond cancer, including treatments ... In an article published Aug. 29 in ... Gates Center for Regenerative Medicine and Stem Cell Biology ...
(Date:8/29/2014)... 29, 2014, 2 PM US Eastern Time)The current ... inject antibodies, commonly produced in animals, to neutralize ... from safety to difficulties in developing, producing and ... New research led by Charles Shoemaker, Ph.D., professor ... Health at the Cummings School of Veterinary Medicine ...
(Date:8/29/2014)... new study from the research group of Dr. John Lewis ... Health Research Institute (London, ON) has confirmed that "invadopodia" play ... published in Cell Reports , shows preventing these tentacle-like ... , Roughly 2 in 5 Canadians will develop cancer ... die of the disease. In 2014, it,s estimated that nine ...
(Date:8/29/2014)... (PRWEB) August 30, 2014 Top10inaction, a ... web conference providers in the online service industry for ... were global leaders Webex, GotoMeeting and Infinite. , With ... users have to determine which provider is ideally a ... conference businesses search for compelling consumer goods and services ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Preventing cancer from forming 'tentacles' stops dangerous spread 2Health News:Top10InAction Reveals Best Web Conference Providers 2
... of Medicine (BUSM), Management (SMG) and Law (LAW), along ... that public-sector research has had a more immediate effect ... findings, which appear as a Special Article in the ... of Medicine , have economic and policy implications. ...
... HealthDay Reporter , WEDNESDAY, Feb. 9 (HealthDay ... cell genome revealed never-before-seen changes in DNA that may ... mapping the full genetic blueprint of the tumor, researchers ... of more targeted drugs and a better understanding of ...
... investing in public parks and recreation sites may be ... healthcare system, according to Penn State researchers. Investments in ... health and fitness, say Geof Godbey, professor emeritus of ... and parks management. "There is a strong relationship between ...
... heart disease, cancers, HIV and other diseases quickly and ... microsponges are an essential component of Rice University,s Programmable ... in the journal Small . The ... and Chemistry, and his colleagues at Rice,s BioScience Research ...
... Family Physicians demonstrates that vulvar cancer occurs most frequently in women ... with vulvar cancer are age 70 or older, and the rate ... by 75 years of age. , A team of researchers headed ... in Women,s Oncology at Women & Infants Hospital of Rhode Island, ...
... Poor memory and problems with other mental skills may be early ... Researchers gave a word recall memory test to 17,851 people, ... measure the brain,s executive functioning skills. The participants, who were aged ... stroke, were then contacted twice a year for up to 4.5 ...
Cached Medicine News:Health News:Researchers find public sector research responsible for many new drug discoveries 2Health News:Researchers find public sector research responsible for many new drug discoveries 3Health News:First Look at Prostate Cancer Genome Yields Insights 2Health News:First Look at Prostate Cancer Genome Yields Insights 3Health News:Key to better health care may be a walk in the park 2Health News:Microsponges from seaweed may save lives 2Health News:Microsponges from seaweed may save lives 3Health News:Researchers: Elderly patients 4 times more likely to die from treatment complications 2Health News:Could Poor Memory Signal Raised Stroke Risk? 2
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Orthopedic Instrument Industry Report, 2014-2017" report to their ... and rising proportion of reimbursement for medical expenses, the ... with its scale presenting a CAGR of 19.2% during ... three product segments of orthopedic instruments in ...
(Date:8/29/2014)... According to a new ... type (SFE, Cold Pressed, Organic Solvent, & Others), and ... Fragrance, & Others) - Global Trends & Forecast ... the Amaranth Seed Oil Market with an analysis ... of value. The Amaranth Seed Oil Market size ...
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2
... Aug. 10, 2011 GNS Healthcare, Inc., (GNS) ... personalized medicine to improve human health, today announced ... Bristol-Myers Squibb Company (NYSE: BMY ) ... and biomarkers in the area of immuno-inflammation.  Utilizing ...
... Ardea Biosciences, Inc. (Nasdaq: RDEA ) announced today ... will present at the Wedbush Securities 2011 Life Sciences Management ... on Tuesday, August 16, 2011. This presentation ... Relations section of Ardea,s website at www.ardeabio.com . Please ...
Cached Medicine Technology:GNS Healthcare Announces Collaboration With Bristol-Myers Squibb 2Ardea Biosciences to Present at Wedbush Securities Life Sciences Conference 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: